Janux Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Janux Therapeutics, Inc. (JANX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 1.05 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-06
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 530.61K shares, a 915.58% increase year-over-year.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 516.20K shares, a 398.51% increase year-over-year.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 229.20K shares, a 8.40% increase year-over-year.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 273.56K shares, a 543.35% increase year-over-year.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 658.56K shares, a 103.71% increase from fiscal 2024.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 323.29K shares, a 71.19% decline from fiscal 2023.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 1.12M shares, a 102.27% increase from fiscal 2022.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 554.78K shares, a 1393.39% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 530.61K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 1.05M shares 10-Q · filed 2026-08-06 | 1.28M shares derived: sum of 3 quarters · filed 2026-08-06 | 1.55M shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 516.20K shares 10-Q · filed 2026-05-07 | 745.40K shares derived: sum of 2 quarters · filed 2026-05-07 | 1.02M shares derived: sum of 3 quarters · filed 2026-05-07 | 1.07M shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 229.20K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 502.77K shares derived: sum of 2 quarters · filed 2026-02-26 | 555.01K shares derived: sum of 3 quarters · filed 2026-02-26 | 658.56K shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 273.56K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 325.81K shares derived: sum of 2 quarters · filed 2025-11-06 | 429.36K shares 10-Q · filed 2025-11-06 | 640.80K shares derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-06-30 | 52.25K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 155.79K shares 10-Q · filed 2025-08-07 | 367.24K shares derived: sum of 3 quarters · filed 2026-02-26 | 409.76K shares derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-03-31 | 103.55K shares 10-Q · filed 2025-05-08 | 314.99K shares derived: sum of 2 quarters · filed 2026-02-26 | 357.51K shares derived: sum of 3 quarters · filed 2026-02-26 | 383.54K shares derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-12-31 | 211.44K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 253.97K shares derived: sum of 2 quarters · filed 2026-02-26 | 279.99K shares derived: sum of 3 quarters · filed 2026-02-26 | 323.29K shares 10-K · filed 2026-02-26 |
| 2024-09-30 | 42.52K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 68.55K shares derived: sum of 2 quarters · filed 2024-11-06 | 111.85K shares 10-Q · filed 2024-11-06 | 591.37K shares derived: sum of 4 quarters · filed 2025-02-27 |
| 2024-06-30 | 26.03K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | 69.33K shares 10-Q · filed 2024-08-07 | 548.85K shares derived: sum of 3 quarters · filed 2025-02-27 | 1.10M shares derived: sum of 4 quarters · filed 2025-02-27 |
| 2024-03-31 | 43.30K shares 10-Q · filed 2024-05-08 | 522.82K shares derived: sum of 2 quarters · filed 2025-02-27 | 1.07M shares derived: sum of 3 quarters · filed 2025-02-27 | 1.13M shares derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-12-31 | 479.52K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 1.03M shares derived: sum of 2 quarters · filed 2025-02-27 | 1.09M shares derived: sum of 3 quarters · filed 2025-02-27 | 1.12M shares 10-K · filed 2025-02-27 |
| 2023-09-30 | 547.87K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 605.74K shares derived: sum of 2 quarters · filed 2023-11-07 | 642.63K shares 10-Q · filed 2023-11-07 | 1.03M shares derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | 57.88K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 94.77K shares 10-Q · filed 2023-08-08 | 477.89K shares derived: sum of 3 quarters · filed 2023-08-08 | 511.92K shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | 36.89K shares 10-Q · filed 2023-05-09 | 420.02K shares derived: sum of 2 quarters · filed 2023-05-09 | 454.04K shares derived: sum of 3 quarters · filed 2023-05-09 | 454.04K shares derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | 383.13K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | 417.15K shares derived: sum of 2 quarters · filed 2023-03-10 | 417.15K shares derived: sum of 3 quarters · filed 2023-03-10 | 554.78K shares 10-K · filed 2023-03-10 |
| 2022-09-30 | 34.02K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 34.02K shares derived: sum of 2 quarters · filed 2022-11-10 | 171.65K shares 10-Q · filed 2022-11-10 | 172.35K shares derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 137.63K shares 10-Q · filed 2022-08-09 | 138.32K shares derived: sum of 3 quarters · filed 2022-08-09 | |
| 2022-03-31 | 137.63K shares 10-Q · filed 2022-05-10 | 138.32K shares derived: sum of 2 quarters · filed 2022-05-10 | ||
| 2021-12-31 | 694.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | 37.15K shares 10-K · filed 2022-03-18 | ||
| 2021-09-30 | 36.45K shares 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |